# Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer

> **NCT00683085** · PHASE1,PHASE2 · TERMINATED · sponsor: **Tokyo University** · enrollment: 2 (actual)

## Conditions studied

- Pancreatic Cancer
- Pancreas Neoplasms

## Interventions

- **BIOLOGICAL:** HLA-A*02:01-restricted VEGFR1-derived peptide vaccination

## Key facts

- **NCT ID:** NCT00683085
- **Lead sponsor:** Tokyo University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-05
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 2 (ACTUAL)
- **Why stopped:** Lack of eligible patient
- **Last updated:** 2011-07-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00683085

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00683085, "Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00683085. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*